Admin Core

管理核心

• 批准号: 10696162
• 负责人: Jean-Pierre J. Issa
• 金额: $ 40.02万
• 依托单位: CORIELL INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-16 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10696162
• 关键词: Address; Administrator; Advocate; Award; Cancer Prognosis; Clinic; Clinical; Clinical Trials; Collaborations; Communication; Complex; Consultations; Data; Decision Making; Development; Electronic Mail; Eligibility Determination; Ensure; Genomics; Grant; Infrastructure; Institution; Interdisciplinary Study; Laboratories; Leadership; Malignant Neoplasms; Medical Research; Minority; Monitor; National Cancer Institute; Outcome; Pathology; Patients; Policies; Preparation; Progress Reports; Protocols documentation; Publications; Quality Control; Regulation; Reporting; Research; Research Activity; Research Infrastructure; Research Personnel; Research Project Grants; Resource Sharing; Strategic Planning; Supervision; Therapeutic Studies; Translational Research; United States National Institutes of Health; Woman; Work; cancer care; cancer therapy; career; clinical research site; data sharing; design; epigenetic therapy; experience; improved; interdisciplinary collaboration; lectures; meetings; novel; novel therapeutic intervention; programs; quality assurance; recruit; screening; success; symposium; web site

PROJECT SUMMARY The Administrative Core will provide essential support to the Coriell Institute for Medical Research (Coriell) and Van Andel Institute (VAI) Epigenetic Therapy SPORE PIs and investigators to maximize success. It will be co- directed by Drs. Jean-Pierre Issa, Stephen Baylin, and Peter Jones, who co-chair the Executive Committee and provide overall supervision of three Projects, two additional Cores, Developmental Research (DRP) and Career Enhancement (CEP) Programs, and scientific direction of the SPORE. The Core Co-Directors will rely on the extensive broad-based scientific, research, and SPORE experience of the Internal and External Advisory Boards in critical decision making. An oversight committee consisting of the SPORE PIs and three clinical experts from the VAI-SU2C team (Drs. Rudin, El-Khoueiry and O’Connell) will ensure prioritization of SPORE trials within the VAI-SU2C team and at clinical sites. Success of the complex interdisciplinary research in the SPORE depends on integration of diverse epigenetic therapy research approaches. The Core will overcome barriers to interdisciplinary collaboration and data sharing and will ensure a unified translational research effort. The SPORE will be founded on planning, integration, and translational research efforts supported by this Core. Its leadership and staff will be responsible for monitoring/planning scientific activities; providing scientific direction; ensuring emphasis on translational research; ensuring interdisciplinary and inter-SPORE integration with major epigenetic therapy programs within/outside Coriell and VAI and other broad translational research activities; and providing optimal administrative and fiscal management. Specific responsibilities of the Core are: oversee and monitor all SPORE activities; promote integration and communication among the SPORE-related clinical programs; monitor the scientific integrity of all projects, and grant awards; assure compliance with institutional, governmental, and National Cancer Institute regulations; oversee the fiscal and budgetary activities of the SPORE; coordinate data control quality assurance issues; coordinate activities associated with clinical trials, including design of protocols, approval by regulatory bodies, implementation, and eligibility screening and assignment of patients to different studies; provide oversight and support for the shared Resources Cores; coordinate and manage meetings of the SPORE Oversight Committee, Executive Committee, Internal and External Advisory Boards, investigator meetings, research meetings, lectures, and symposia; administer the DRP and the CEP; coordinate interdisciplinary and inter-SPORE interactions and exchanges/meetings with other Epigenetic Therapy SPORE programs and investigators, and other SPORE programs; administer the activities of the Patient Advocates; comply with, and improve policies addressing recruitment and retention of women and minorities; and maintain a Epigenetic Therapy SPORE website focused on issues in epigenetic therapy translational research in cancers.

项目摘要 行政核心将为科利尔医学研究所（科利尔）提供必要的支持， 货车安德尔研究所（VAI）表观遗传疗法孢子PI和研究人员，以最大限度地提高成功。它将是- 由Jean-Pierre Issa博士、Stephen Baylin博士和Peter Jones博士指导，他们是执行委员会的联合主席， 提供三个项目的全面监督，两个额外的核心，发展研究（DRP）和职业生涯 增强（CEP）计划，和科学方向的孢子。核心联席董事将依靠 内部和外部咨询委员会的广泛科学、研究和SPORE经验 关键的决策。监督委员会由SPORE PI和三名来自 VAI-SU 2C团队（Rudin、El-Khoueiry和O 'Connell博士）将确保在 VAI-SU 2C团队和临床研究中心。SPORE复杂的跨学科研究的成功取决于 关于整合不同的表观遗传治疗研究方法。核心将克服障碍， 跨学科合作和数据共享，并将确保统一的翻译研究工作。孢子 将建立在该核心支持的规划，整合和转化研究工作的基础上。其领导 工作人员将负责监测/规划科学活动;提供科学指导;确保 强调转化研究;确保与主要表观遗传学的跨学科和孢子间整合 Coriell和VAI内外的治疗计划以及其他广泛的转化研究活动;并提供 优化行政和财政管理。核心的具体职责是：监督和监测所有 SPORE活动;促进SPORE相关临床项目之间的整合和沟通;监测 所有项目的科学完整性，并授予奖项;确保遵守机构，政府和 国家癌症研究所法规;监督SPORE的财政和预算活动;协调数据 控制质量保证问题;协调与临床试验相关的活动，包括方案设计， 监管机构的批准、实施、合格性筛选和将患者分配到不同的 研究;为共享资源核心提供监督和支持;协调和管理 SPORE监督委员会、执行委员会、内部和外部咨询委员会、调查员 会议，研究会议，讲座和研讨会;管理DRP和CEP;协调 与其他表观遗传学治疗的跨学科和孢子间的互动和交流/会议 计划和研究者，以及其他SPORE计划;管理患者倡导者的活动; 遵守并改进有关征聘和留用妇女和少数族裔的政策; 一个表观遗传疗法SPORE网站，专注于癌症表观遗传疗法转化研究的问题。